Literature DB >> 23242514

The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane.

Arik Dahan1, Avital Beig, Viktoriya Ioffe-Dahan, Riad Agbaria, Jonathan M Miller.   

Abstract

The purposes of this study were to assess the efficiency of different nifedipine amorphous solid dispersions (ASDs) in achieving and maintaining supersaturation and to investigate the solubility-permeability interplay when increasing the apparent solubility via ASD formulations. Spray-dried ASDs of nifedipine in three different hydrophilic polymers, hydroxypropyl methylcellulose acetate succinate (HPMC-AS), copovidone, and polyvinylpyrrolidone (PVP), were prepared and characterized by powder X-ray diffraction and differential scanning calorimetry. The ability of these formulations to achieve and maintain supersaturation over 24 h was assessed. Then, nifedipine's apparent intestinal permeability was investigated as a function of increasing supersaturation in the parallel artificial membrane permeability assay model and in the single-pass rat intestinal perfusion model. The efficiency of the different ASDs to achieve and maintain supersaturation of nifedipine was found to be highly polymer dependent; while a dispersion in HPMC-AS enabled supersaturation 20× that of the crystalline aqueous solubility, a dispersion in copovidone enabled 10×, and PVP allowed supersaturation of only 5× that of the crystalline solubility. Nifedipine flux across the intestine from supersaturated solutions was increased, and the apparent intestinal permeability was constant, irrespective of the degree of supersaturation or the polymer being used. In conclusion, while with other solubility-enabling approaches (e.g., surfactants, cyclodextrins, cosolvents), it is not enough to increase the apparent solubility, but to strike the optimal solubility-permeability balance, which limits the chances for successful drug delivery, the amorphous form emerges as a more advantageous strategy, in which higher apparent solubility (i.e., supersaturation) will be readily translated into higher drug flux and overall absorption.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23242514      PMCID: PMC3675758          DOI: 10.1208/s12248-012-9445-3

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  30 in total

Review 1.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

Review 2.  Drugs as materials: valuing physical form in drug discovery.

Authors:  Colin R Gardner; Christopher T Walsh; Orn Almarsson
Journal:  Nat Rev Drug Discov       Date:  2004-11       Impact factor: 84.694

3.  A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.

Authors:  Jonathan M Miller; Avital Beig; Robert A Carr; Julie K Spence; Arik Dahan
Journal:  Mol Pharm       Date:  2012-06-20       Impact factor: 4.939

4.  A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.

Authors:  G L Amidon; H Lennernäs; V P Shah; J R Crison
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

5.  Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.

Authors:  Arik Dahan; Gordon L Amidon
Journal:  Pharm Res       Date:  2008-12-02       Impact factor: 4.200

Review 6.  Intestinal permeability and its relevance for absorption and elimination.

Authors:  H Lennernäs
Journal:  Xenobiotica       Date:  2007 Oct-Nov       Impact factor: 1.908

Review 7.  Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.

Authors:  Arik Dahan; Amnon Hoffman
Journal:  J Control Release       Date:  2008-04-01       Impact factor: 9.776

8.  The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.

Authors:  Arik Dahan; Hairat Sabit; Gordon L Amidon
Journal:  AAPS J       Date:  2009-03-25       Impact factor: 4.009

9.  Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.

Authors:  Arik Dahan; Gordon L Amidon
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

10.  Segmental-dependent membrane permeability along the intestine following oral drug administration: Evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat.

Authors:  Arik Dahan; Brady T West; Gordon L Amidon
Journal:  Eur J Pharm Sci       Date:  2008-11-05       Impact factor: 4.384

View more
  11 in total

1.  Ranking Itraconazole Formulations Based on the Flux through Artificial Lipophilic Membrane.

Authors:  Konstantin Tsinman; Oksana Tsinman; Ram Lingamaneni; Saijie Zhu; Bernd Riebesehl; Arnaud Grandeury; Michael Juhnke; Bernard Van Eerdenbrugh
Journal:  Pharm Res       Date:  2018-06-20       Impact factor: 4.200

2.  Advantageous Solubility-Permeability Interplay When Using Amorphous Solid Dispersion (ASD) Formulation for the BCS Class IV P-gp Substrate Rifaximin: Simultaneous Increase of Both the Solubility and the Permeability.

Authors:  Avital Beig; Noa Fine-Shamir; David Lindley; Jonathan M Miller; Arik Dahan
Journal:  AAPS J       Date:  2017-02-15       Impact factor: 4.009

Review 3.  A Critical Overview of the Biological Effects of Excipients (Part I): Impact on Gastrointestinal Absorption.

Authors:  Marilyn N Martinez; Balint Sinko; Fang Wu; Talia Flanagan; Enikő Borbás; Eleftheria Tsakalozou; Kathleen M Giacomini
Journal:  AAPS J       Date:  2022-05-02       Impact factor: 4.009

4.  Role of Surfactants on Release Performance of Amorphous Solid Dispersions of Ritonavir and Copovidone.

Authors:  Anura S Indulkar; Xiaochun Lou; Geoff G Z Zhang; Lynne S Taylor
Journal:  Pharm Res       Date:  2022-02-15       Impact factor: 4.200

Review 5.  Better and greener: sustainable pharmaceutical manufacturing technologies for highly bioavailable solid dosage forms.

Authors:  Serena Bertoni; Dritan Hasa; Beatrice Albertini; Beatrice Perissutti; Mario Grassi; Dario Voinovich; Nadia Passerini
Journal:  Drug Deliv Transl Res       Date:  2022-01-06       Impact factor: 5.671

Review 6.  Drug-Rich Phases Induced by Amorphous Solid Dispersion: Arbitrary or Intentional Goal in Oral Drug Delivery?

Authors:  Kaijie Qian; Lorenzo Stella; David S Jones; Gavin P Andrews; Huachuan Du; Yiwei Tian
Journal:  Pharmaceutics       Date:  2021-06-15       Impact factor: 6.321

7.  Hydrotropic Solubilization of Lipophilic Drugs for Oral Delivery: The Effects of Urea and Nicotinamide on Carbamazepine Solubility-Permeability Interplay.

Authors:  Avital Beig; David Lindley; Jonathan M Miller; Riad Agbaria; Arik Dahan
Journal:  Front Pharmacol       Date:  2016-10-25       Impact factor: 5.810

8.  Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect.

Authors:  Rudra Pangeni; Jeong Uk Choi; Vijay Kumar Panthi; Youngro Byun; Jin Woo Park
Journal:  Int J Nanomedicine       Date:  2018-06-06

9.  Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations.

Authors:  Avital Beig; Riad Agbaria; Arik Dahan
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

10.  Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development.

Authors:  Omri Wolk; Riad Agbaria; Arik Dahan
Journal:  Drug Des Devel Ther       Date:  2014-09-24       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.